(NASDAQ: MRNA) Moderna's forecast annual revenue growth rate of -2.11% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 49.9%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 11.74%.
Moderna's revenue in 2025 is $5,081,000,000.On average, 8 Wall Street analysts forecast MRNA's revenue for 2025 to be $885,431,149,508, with the lowest MRNA revenue forecast at $704,189,656,883, and the highest MRNA revenue forecast at $1,147,380,481,634. On average, 8 Wall Street analysts forecast MRNA's revenue for 2026 to be $1,248,806,912,079, with the lowest MRNA revenue forecast at $896,621,266,634, and the highest MRNA revenue forecast at $2,069,473,223,996.
In 2027, MRNA is forecast to generate $1,923,200,895,492 in revenue, with the lowest revenue forecast at $1,074,014,965,967 and the highest revenue forecast at $3,086,238,844,220.